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ABSTRACT
Abstract: Solid eye platelet-rich plasma (E-PRP)
concentratesplatelets ina small volumeofplasma
which contains a high concentration of
important growth factors and cell adhesion
molecules. These cell adhesion molecules and
growth factors occupy a major role in wound
healing and enhance the physiological procedure
at the site of the injury or the surgery. There are
different materials used to tectonically maintain
the solid clot attached at the site where treatment
is necessary. Although AM may be used for this
purpose, other biomaterials such a bovine
pericardium or autologous fibrin membrane are
at least as effectivewith less interdonor variations,
no biological hazards, providing a better surgical
alternative than the biologically so variable
amniotic membrane patch. Solid platelet-rich
plasma in the form obtained in ophthalmology,
E-PRP, is a reliable and effective surgical
coadjuvant to promote corneal wound healing
in severe corneal ulcers and corneal perforations,
and may be associated with other ocular surface
reconstruction procedures.
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INTRODUCTION
Severe ocular surfacedisease (OSD)due to thermal
and chemical burns, Stevens–Johnson syndrome
(SJS), ocular cicatricial pemphigoid (OCP)orother
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conditions currently poses a serious clinical
challenge for ophthalmologists’ worldwide [1].
In these cases, the corneal epithelial stem cells
located in the corneal limbus are destroyed, and
physiological healing of the ocular surface may
not be possible spontaneously, causing corneal
perforation or coverage of the corneal surface by
invading neighbouring conjunctival epithelial
cells resulting in neovascularization, chronic
inflammation, ingrowth of fibrous tissue and
stromal scarring. The treatment of ocular surface
disorders has a multifactor approach and
conventional treatments are often not enough
to solve the problem. In patients with severe
ocular surface disease, the success of amniotic
membrane in treating ulcers and/or perforations
is less than 20% [2, 3]. Investigators have been
searching for a long time for a product that would
be similar to tears in composition and activity
and, which may incite the regeneration of the
tissues affected in ocular surface disorders.
Plasma-derived products have shown an
important role in the treatment of ocular surface
disorders [2–5].
Plasma, unlike serum, does contain clotting
proteins of full blood such as fibrinogen, and as
platelets are great reservoirs of growth factors,
contains a higher concentration of these
components than the acellular part of the
blood, the serum [6]. Platelet-rich plasma (PRP)
is a portion of the plasma fraction of blood
having a platelet concentration above baseline.
Autologous PRP is obtained by means of double
centrifugation, where after the platelets are
activated just prior to clinical use. The final
concentration is at least 1,000,000 platelets/lL.
The preparation contains platelet-derived
growth factors and other molecules considered
to have healing properties [7], unlike artificial
tears, and have pH, osmolarity and
biomechanical properties which resemble
natural tears [8].
The eye platelet-rich plasma (E-PRP) used in
ophthalmology is a preparation of autologous
plasma, rich in platelets, but with a different
platelet concentration from the PRP preparation
described by Marx et al. [7] in which a double
centrifugation is done to concentrate the
platelets. The E-PRP uses sodium citrate as an
anticoagulant and when necessary calcium
chloride is used for the activation of the E-PRP
in its solid or clot formulation. Plasma rich in
growth factors (PRGF) [9] is another platelet rich
preparation in which after a first centrifugation,
the platelets are activated using calcium
chloride in the liquid or eye drop formulation.
PRGF uses a commercial kit to obtain the blood
and a specific laboratory centrifuge is used for
plasma separation. E-PRP does not require
specific devices (Fig. 1).
The E-PRP fabrication is carried out using a
one-step centrifugation process and the final
platelet concentration depends on whether it
will be used as an eye drop for topical
application (without activation) or as a clot
(activated with calcium chloride), for surgical
procedures such as ocular reconstruction or
treatment of corneal perforations.
The aim of this review is to comprehensively
appraise the state of the art with regard to the
use of blood-derived products in corneal
surgery.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RATIONALE FOR USE
Different blood-derived formulations, such as
autologous serum, plasma enriched with
platelets and preparations rich in growth
factors have been used to promote wound
32 Ophthalmol Ther (2016) 5:31–45
healing in multiple tissues. Blood-derived
products have demonstrated their capacity to
increase healing and stimulate the regeneration
of different tissues supplying growth factors and
other bioactive molecules that are present in the
blood [10].
Serum is the clear fluid that is obtained
during blood coagulation after blood cells and
clotting proteins have been removed. Since Fox
et al. [11] first used autologous serum eye drops
in the treatment of keratoconjunctivitis sicca, it
has been the preferred blood-derived topical
preparation used in the treatment of ocular
surface diseases. Autologous serum has been
found to be effective in the treatment of
persistent epithelial defects [12], neurotrophic
ulcers [13], superior limbic keratoconjunctivitis
[14] and dry eye conditions such as
graft-versus-host disease [15] or after LASIK
[16]. Autologous serum has also been used as
an adjunctive treatment in ocular surface
reconstruction with variable results [17, 18].
Unlike artificial tears, serum eye drops have pH,
osmolarity and biomechanical properties that
resemble natural tears, and they are
non-preserved. Used topically they supply
essential nutrients to the ocular surface such
as growth factors, vitamins and bacteriostatic
products such as IgG, lysozyme and
complement [19]. Therefore, they potentially
provide lubrication, and have epitheliotrophic
and antimicrobial properties that are not found
in commercialised artificial tears.
Plasma, unlike serum, does contain the
clotting proteins found in blood itself, such as
fibrinogen. Although the plasma itself contains
growth factors, platelets are also great reservoirs
of growth factors that have the potential to
enhance cell proliferation and wound healing.
The alpha-granules in platelets contain many
bioactive proteins such as epidermal growth
factor (EGF), platelet derived growth factor AB
(PDGF-AB), vascular endothelial growth factor
(VEGF), insulin-like growth factor (IGF-1),
transforming growth factor beta (TGF-b), as
well as cytokines including proteins such as
CD40L and PF4, which promote tissue repair
and affect angiogenesis and inflammation [10].
Growth factors released from activated platelets
initiate and modulate wound healing in both
soft and hard tissues [20, 21]. The plasma also
contains concentrated quantities of some
important cell-adhesion molecules which
promote epithelial migration such as
fibrinogen, fibronectin and vitronectin [6].
Laboratory research with different cultured
cellular lines such as tendon cells, synovial
and skin fibroblasts and corneal epithelial cells,
shows the multiple benefits and biological
effects of growth factors, including
proliferation, differentiation and healing [19,
22–24].
Fig. 1 Obtaining procedure of eye platelet-rich plasma (E-PRP)
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Dormant corneal ulcers are persistent
epithelial defects that fail to heal in spite of at
least 2 weeks of conventional treatment, and
are most commonly caused by neurotrophic
keratopathy (including metaherpetic disease),
dry eye or immunological disorders such as
rheumatoid arthritis or ocular cicatricial
pemphigoid. In a prospective study, Alio´ et al.
[25] included 26 eyes with dormant corneal
ulcers with neurotrophic keratopathy (n = 12)
(Fig. 2a), herpetic keratopathy (n = 9) and ulcers
of immunological origin (n = 5). They were
treated for 15 days with E-PRP eye drops at a
dose of six times a day in addition to routine
medication. Primary outcome measures were
the decrease in size or depth of the corneal ulcer
and recovery of vision. Secondary outcome
measures were the reduction of discomfort or
pain, decrease in conjunctival hyperemia, or
conjunctival oedema if present. Significant
clinical improvement was found in 92% of the
eyes (24/26), with a complete resolution of the
ulcer in 50% of the cases (13/26) (Fig. 2b). Only
two eyes did not show significant improvement
after the treatment. Reduction in inflammation
and decrease of ocular pain were the other
parameters that clearly improved in the
majority of the cases. Two eyes of two
different patients with a recidivant epithelial
defect, defined as observation of a new
epithelial defect in the same place of the
previous ulcer with positive fluorescein
staining under slit-lamp examination, occurred
after 6 months to 1 year and were treated
successfully by keratoplasty. Visual acuity also
improved in more than half of the patients,
with 31% of the eyes gaining 1–3 lines of visual
acuity, 15% with an improvement of 4–5 lines
of visual acuity, and 12% with more than 6 lines
of improvement. A reduction in inflammation
was observed after 1 or 2 weeks, with a decrease
in ocular pain. This report showed that E-PRP
improved, pain, inflammation and
photophobia; enhanced reepithelialisation,
promoting corneal wound healing and
improving the clinical condition, which in the
end, resulted in improved vision in the most of
the patients studied.
PRP has been used previously by our group
and others in small series of patients to treat
several ocular surface problems with good
results [26, 27].
Fig. 2 a Neurotrophic ulcer patient before treatment with eye platelet-rich plasma (E-PRP). b Same patient in a after
1 month of treatment with topical E-PRP
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PLATELET-RICH PLASMA
AS A SURGICAL ADJUVANT TOOL
IN SEVERE CORNEAL ULCERS
AND PERFORATIONS
E-PRP and PRGF have been successfully used as
a component for tissue regeneration procedures
such as reconstructive orthopaedic surgery,
plastic surgery, and oral and maxillofacial
surgery [28–30]. In dental implant surgery the
use of autologous platelet-rich clot has been
shown to accelerate ossification after a tooth
extraction or around titanium implants, with
improved success rate and marked reductions in
the time required for implant stabilization
[31–33].
In articular surgery [34] and tendon repair
[35] autologous platelets have also been shown
to accelerate healing. Concentrated platelet
preparations are also used to induce bone
regeneration when prosthetic devices are to be
implanted [36] in implant and maxillofacial
surgery. Platelets derivatives are also used in
traumatology, combined with hydroxyapatite,




E-PRP can be used to promote and enhance
healing during ocular surface reconstruction
procedures or to treat impending perforation
or even frank perforations. In theory, clot E-PRP
should provide a higher amount of growth
factors in an initial burst as well as late
synthesis and secretion of growth factors for
the remaining 7 days of the lifespan of a platelet
[40]. Patients are screened for HVB, HVC and
HIV, the presence of active infection is a
contraindication for manipulation of
blood-derived products in the laboratory.
The manipulation of the blood to prepare
autologous E-PRP must be done under sterile
conditions using a laminar flow cabin [6]. For
this purpose, between 40 and 60 mL of blood
is extracted from the patient just before the
surgery. Blood is centrifuged by the one-step
process as previously described for the E-PRP
eye drop formulation [6]. However in this
case, only the plasma in the region of the red
cell column is harvested, avoiding the white
blood cell layer, the ‘buffy coat’, in order to
avoid the undesirable proinflammatory effects
of leucocyte products. One millilitre of E-PRP
is placed into each well tissue culture plate
and 50–60 ll of Braun 10% calcium chloride
are added for activation. The mix is
homogenized gently using an sterile tip, and
placed at 37 C in an incubator for half an
hour. After that time, the E-PRP clot is formed
and it is ready to be applied onto the ocular
defect immediately afterwards (Fig. 3). In the
E-PRP clot the platelet enrichment
corresponds to a number density that is
about 2–3 times that of full blood [6].
Fig. 3 Aspect of a clot of eye platelet-rich plasma (E-PRP)
immediately after its preparation
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SOLID E-PRP COMBINED WITH
THE USED OF AMNIOTIC
MEMBRANE TRANSPLANTATION
Ocular surface reconstruction includes limbal
autograft or allograft keratoplasty, amniotic
membrane transplantation (AMT), sectorial
epitheliectomy, etc. Theoretically, the
adjuvant use of E-PRP would enhance the
regenerative effect of these interventions, by
release of growth factors that promote wound
healing and decrease inflammation. Other
biologically active products such as autologous
serum have been used successfully for this
purpose [17].
Alio´ et al. [25] presented a series of cases with
perforated eyes or high probability of
perforation due to deep chronic corneal ulcers
treated with AMT combined with a clot of
autologous E-PRP. Surgery consisted of wound
debridement, excision and removal of
devitalized tissue with a posterior application
of AM to the wound site with the epithelial side
up. A clot of autologous E-PRP was inserted
beneath the AM to seal the imminent or
existing corneal perforation with an increase
in the therapeutic effect of the AM (Fig. 4). The
membrane was sutured in place to the
conjunctiva using a 10-0 nylon suture and a
running purse-string suture was applied so that
the membrane tightly adhered to the entire
corneal surface. The eye was closed with a
provisional tarsorrhaphy. Initial outcome
measures were the decrease in size or depth of
the corneal ulcer and improvement in
best-corrected visual acuity. All patients
showed an improvement in the size of the
ulcer, and 71% (10/14 eyes) had complete
resolution. Vision also improved in 57% of the
cases (8/14 eyes) along with a decrease in
inflammation that occurred 1–2 weeks after
the surgery. It cannot be ascertained in this
kind of ocular surface alterations whether the
healing effect of the E-PRP in combination with
AM was higher than using AM alone. However,
theoretically, E-PRP use together with AM
should additionally encourage corneal wound
healing processes and further decrease
inflammation due to the effect of E-PRP.
We also have experience (unpublished data)
with the use of E-PRP clot in other surgical
interventions to restore the ocular surface such
as limbal keratoplasty (Fig. 5) with good results,
as seen with autologous serum by other authors
[17, 18]. We believe that the prolonged
synthesis and release of growth factors by the
E-PRP clot provides additional long acting that
would increase the benefit of E-PRP over
autologous serum [40].
SOLID E-PRP COMBINED WITH
THE USE OF BOVINE PERICARDIUM
(TUTOPATCH)
In the previous section we defined the use of
combined solid E-PRP and amniotic membrane
(AM) for the management of impending or
actual perforations. The autologous
platelet-rich preparation was used to stimulate
tissue regeneration, and to induce epithelial
and mesenchymal cells to migrate and
proliferate to restore the site of the injury. The
role of the AM was to conserve the solid clot
attached at the damaged surface. We carried out
a pilot study [41] to use a commercially
available collagenous membrane obtained
from bovine pericardium as an alternative to
AM for the management in emergency cases.
This membrane was designed to repair, support
and replace the connective tissue. Unlike
amniotic membrane, the commercially
available bovine pericardium does not need
specific authorization to be used as a graft, and
36 Ophthalmol Ther (2016) 5:31–45
it is a completely inert material underwent to a
procedure of dehydration, purification,
deantigenation and sterilization resulting in
an acellullar tissue structure free of pathogens,
antigens, prions and any other non-collagen
protein. Moreover there are no interdonor
variations as it has been observed with
amniotic membrane [42].
The bovine pericardium patch used was
Tutopatch (Tutogen Medical GmbH,
Neunkirchen, Germany). The use of Tutopatch
has been described in cardiovascular surgery
[43] for closure of ventricular septal defects, for
dural substitution in a variety of neurosurgical
procedures [44], and in ophthalmology in cases
of patients with orbital fracture where a
reposition of the floor is needed [45]. In
patients who undergo enucleation for uveal
melanoma, wrapping of hydroxyapatite
implants with bovine pericardium has been
suggested as a safe alternative with a lower
rate of complications and a decreased surgical
time compared to other procedures with
autologous tissue that needs to be harvested
[46]. In cases of glaucoma needing surgery, a
double layer of Tutopatch has been used in
conjunction with the implantation of a valve
Ahmed in a patient with necrotizing scleritis
[41].
In our pilot study [41] we included six
patients with different types of corneal
perforations caused by a chronic corneal
Fig. 4 a Corneal perforation patient before amniotic
membrane transplantation (AMT). b Application and
partial suture of amniotic membrane on corneal
perforation. c Placing eye platelet-rich plasma (E-PRP) clot
below the AM. d Final result after AMT with E-PRP clot
in the perforated eye
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ulcerative disorder. There were three cases of
ocular cicatricial pemphigoid, two neurotrophic
ulcers and one corneal decompensation. None
of them demonstrated signs of active infection
at the time of the operation. The eyelids were
separated and the epithelium was debrided
1.0–1.5 mm from the perforation. The
pericardial patch was then moistened with an
antibiotic solution with 1% cefuroxime until it
became a flexible membrane. The pericardium
membrane was then trimmed to conform to the
shape of the eye. Then a 10-0 nylon-running
suture was used to suture the Tutopatch to the
180 inferior conjunctiva (Fig. 6). For the
preparation of the clots of E-PRP, 1 mL of the
PRP is placed into each four-well tissue culture
plate (Nunc), and 50 mL of 10% calcium
chloride (Braun) are added to each well for
activation. Clots of E-PRP were then placed into
the site of the perforation and over the debrided
area beneath the collagenous membrane.
Additional sutures were used to fix the
membrane to the remainder of the
conjunctiva. At the end of the procedure, a
temporary and partial tarsorrhaphy was
performed to allow observation of the central
cornea with the slit lamp. In all cases a firm non
hypotonic ocular globe was assessed by digital
examination. No evidence of infection or
inflammation was detected in any of the cases.
Two or 3 weeks after the surgery, the temporal
tarsorrhaphy was opened in all patients and the
Fig. 5 a Patient with limbar deﬁciency before surgery.
b Limbal keratoplasty before application of eye platelet-rich
plasma (E-PRP) clot and collagen membrane. c Placing
Tutopatch on limbal keratoplasty. d Application of E-PRP
clot under Tutopatch after limbal keratoplasty
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ocular surface was analyzed. In all cases the
corneal perforation was sealed up with no
evidence of leakage even when moderate
pressure was applied to the globe. No relapses
of the ulcerative corneal condition or
perforation in five of the cases before the
performance of the definitive corneal grafting
surgery. Only patient 6, with severe ocular
cicatricial pemphigoid and long history of
limbal stem cell deficiency with two previous
limbal stem cell transplantation suffered a
relapse, and a penetrating keratoplasty was
performed 1 month after the Tutopatch
procedure.
In summary, both E-PRP clot and bovine
pericardium can be successfully combined for
the management of all the perforations to take
advantage of the effect of E-PRP growth factors
and the tectonic properties of the Tutopatch,
although the number of patients in the study
was reduced. This technique has a low
biological risk, and can be proposed as an
accessible and natural active solution for the
urgent management of perforated corneal
ulcers.
SOLID E-PRP COMBINED WITH
THE USE OF AN AUTOLOGOUS
FIBRIN MEMBRANE
Corneal perforation constitutes a major
ophthalmic emergency necessitating surgical
intervention because of the severity and major
consequences, such as infection, severe
Fig. 6 a Neurotrophic corneal ulcer with high risk of perforation. b Application of Tutopatch on the ulcer and partial
suture. c Placing E-PRP clot under the collagen membrane. d Eye of the same patient, 1 month postoperatively
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anatomical distortion of the anterior segment of
the eye, retinal detachment, phthisis bulbi and
total blindness [47]. These perforations are the
result of trauma and ulcerative diseases of
different conditions.
Perforation can be managed with the use of
sealants such as cyanoacrylate [48], or using
different types of patches such as autologous
conjunctival flaps [49], or more commonly
multilayer AM transplants [50]. Corneal
grafting is usually delayed as much as possible
to improve the clinical condition and therefore
surgical success [51]. Moreover, in many cases
there may not be corneal tissue readily
available. AM transplants can be considered
now as one of the preferred options to treat
corneal perforations, especially if the size of the
perforation is big for ocular adhesives like
cyanoacrylate. However, AM is an uneven
biological tissue with different properties and
efficacy depending on the method of processing
and preservation [42]. It may introduce major
biological hazards such as viral contaminants
and prions [50], and in some countries needs
specific authorization to be used as a grafting
tissue.
For all these reasons we developed an
autologous fibrin patch, 100% autologous,
which can be easily handled because its
consistency and thickness (Fig. 7), and can be
used with E-PRP as clot as we had done with AM
[6] or Tutopatch [41]. The fibrin strands of the
patch can bind to the clot and at the same time
to the stromal collagen fibers of the cornea, thus
contributing to sealing the defect. The fibrin
patch and platelet clot gradually disappear over
the wound, constituting an autologous,
physiological and biological active solution for
corneal perforation.
Preparation of the autologous fibrin
membrane requires a glass beaker previously
sterilized. Working inside a laminar flow hood,
5 mL of platelet-poor plasma are placed in the
beaker together with 500 lL of 10% calcium
chloride and 1 mL of previously prepared
autologous thrombin. Autologous thrombin is
obtained by activation of 3 mL of E-PRP with
300 lL of 10% calcium chloride, and placed in
an incubator for 30 min at 37 C. After the
contents are mixed carefully, the beaker was
incubated at 37 C for 1 h. During this time, the
plasma fibrinogen, which is soluble, converts
into fibrin, which is insoluble and viscous. After
the incubation period, the fibrin membrane
obtained is circular, with a diameter between 18
and 22 mm, and approximately 1 mm thick.
With these properties, the fibrin membrane is
perfectly manageable and suitable for applying
to the damaged ocular surface.
Combined autologous fibrin membrane and
E-PRP clot has been used with success in our
clinic and results have been published [47]. We
included 11 patients with central corneal
perforations caused by a chronic corneal
ulcerative disorder. In three cases the
perforation was partially blocked by
intraocular tissue, particularly the iris. The
epithelium was debrided with a sponge
1.0–1.5 mm from the perforation (Fig. 8). The
fibrin membrane was then dried on an
Fig. 7 Aspect of two pieces of ﬁbrin membrane immedi-
ately after their preparation
40 Ophthalmol Ther (2016) 5:31–45
absorbent sterile paper until it appeared to be a
solid, fibrous structure. A 10-0 nylon-running
suture was used to sew the fibrin membrane to
the 180 inferior conjunctiva. Solid platelet-rich
plasma clots were then placed onto the corneal
perforation and the epithelial debrided area
underneath the fibrin membrane. Additional
stitches were used to fixate the fibrin membrane
to the remainder of the conjunctiva. The fibrin
and E-PRP clots were placed in the same manner
when there was iris or other intraocular tissue
blocking the perforation. A partial tarsorrhaphy
was performed to allow observation of the
central cornea with the slit lamp at the end of
the procedure. In all cases, the corneal
perforation was sealed. The fibrin membrane
was present on the corneal surface for the first
3–5 days and then gradually disappeared. No
evidence of infection or inflammation was
detected in any of the cases. Finger pressure
confirmed the presence of acceptable levels of
ocular tonus in all cases from day 2 after the
operation. After 7 days, the tarsorrhaphy was
removed from all patients and the ocular
surface was inspected. In all cases the corneal
perforation was sealed with no evidence of
Fig. 8 Intraoperative steps of the surgical technique.
a Large central corneal perforation. b The ﬁbrin membrane
is extended over the perforated cornea and sutured to the
inferior conjunctiva. c The eye platelet-rich plasma (E-PRP)
clot is placed underneath the ﬁbrin membrane. d The
upper portion of the membrane is sutured to the
conjunctiva
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leakage even when moderate pressure was
applied to the globe (Fig. 9). No relapses of the
ulcerative corneal condition or perforation
occurred in any of the cases.
Our findings combined with research on this
topic suggest that combined use of autologous
fibrin membrane and E-PRP clot is a safe and
effective alternative for the closure of corneal
perforations. The obvious advantage of this
technique is the use of autologous material for
surgery. We believe that with specialized
technicians and resources, the preparation of
E-PRP and autologous fibrin membrane is
possible in most tertiary hospitals.
CONCLUSION
Solid, platelet-enriched plasma in the form
obtained in ophthalmology, E-PRP, is a
reliable and effective surgical coadjuvant to
promote corneal wound healing in severe
corneal ulcers and corneal perforations, and
may be associated to other, ocular surface
reconstruction procedures. Solid E-PRP
concentrates platelets in a small volume of
plasma which contains a high concentration
of essential growth factors and cell adhesion
molecules. These growth factors and cell
adhesion molecules occupy a major role in
wound healing and enhance the physiological
process at the site of the injury/surgery.
Different materials are used to maintain the
solid clot attached at the site where treatment
is necessary. For these purposes, AM or other
biomaterials such as bovine pericardium or
autologous fibrin membrane can be used with
different grades of interdonor variations or
biological hazards, providing surgical
alternatives to be used depending of the
availability of them.
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